Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy

Hajir A Al Saihati, Ph D*

ABSTRACT

Immunity is the outcome of a complicated interaction among the passive immune system (antigen-agnostic) in addition to the active immune system (antigen-specific) (which is antigen-specific). Non-clonal recognition receptors, such as NOD-like receptors (NLRs), lectins, Toll-like receptors (TLRs), and helicases, are used via passive immune system's molecules and cells. The active immune system's B cells and T cells utilize clonal receptors to identify antigens or their generated peptides in a very precise manner.

Ralph Steinman has the Nobel prize for the innovation of Dendritic Cells (DC), an occasional cell kind which is one of the vital cellular sensors of microbes. The DCs are related to their micro-environment via a prosperity of molecular antennae which permit them to arrest attacking microorganisms in addition to convey the resultant data to lymphocytes. Therefore, DCs offer a vital connection among the primary and secondary immune responses.

INTRODUCTION

Number of people being treated for cancer was increasing at a greater rate than it had ever been before. Despite the fact that current therapeutic techniques such as radiation, chemotherapy, as well as surgical operation have greatly enhanced the consequence of cancer patients, their efficacy is insufficient in the majority of cases. As a result, new therapeutic techniques, including as cancer immunotherapy, were being developed. Malignancy immunotherapy aims to prompt or enhance existing tumor-specific immune responses by selectively destroying tumor cells while avoiding the severe side effects of traditional "slash and burn" treatments. The policies that were under improvement could be approximately allocated into passive and active immunotherapy approaches[1].

The patient's immune system capacity to identify malignant cells from healthy cells centered on tumor antigen expression is required for active targeted immunotherapy. Dendritic cell (DC)-based techniques are one among the most popular outstanding and safe ways to treat cancer in this category. The foundation of this treatment was the usage of the person's own DCs, which were then coated with antigens that resembled the cancerous cells. These DCs prompted antigen-specific T cells to multiply and develop into effector cells which could identify and kill the cells of malignant tumor which independent of their place when adequately primed. Furthermore, activated T cells establish an immunological memory and so assist as the primary line of defense mechanism against recurrent malignant cells due to their capability to detect and destroy circulating malignant tumor cells[2].

Passive immunotherapy, in disparity to active immunotherapy, which delivers ‘ready-to-use' strategies for improving anti-tumor immune responses. Two types of passive immunotherapy have attracted attention as a consequence of their most recent achievements in clinical trials, resulting in the editorial board of the magazine Science declaring malignancy immunotherapy as the "innovation of the year 2013"[3].

These included the usage of therapeutic antibodies to regulate T-cell reactivity along with the usage of cancer-specific T cells grown in vitro. Pen et al. (2014) used the inhibition of immunological checkpoints including the communication of cytotoxic T lymphocyte antigen 4 (CTLA-4), CD80 (B7.1)/CD86 (B7.2), programmed death receptor 1 (PD-1-CD279) and its ligand PD-L1 to demonstrate the success of antibody-based therapy (CD274-B7-H1). Passive immunotherapy has also benefited from chimeric antigen receptor-modified T cells or genetically altered T cells that can identify antigens on cancer cells without relying on the human leukocyte antigen (HLA) system.

The grouping of multiple cytotoxic medications, as well known, was a common method in clinical oncology for improving the success of malignant treatment. In the field of cancer immunotherapy, a similar example was developing. Immunotherapeutic techniques could be used as a supplement to traditional cancer treatments, either alone or in combination with other treatments[4].

The DC-centered therapy will be discussed in this review. We'll discuss known DC sources and successful DC immunogenicity, as well as ways to improve presentation and the source of antigen, develop novel immune adjuvants, as well as look for associated chemotherapeutic or immunomodulation.

DENDRITIC CELL VACCINES

DCs are the most dominant antigen-presenting cells (APCs), accomplished of activating immature and memory CD8 (cytotoxic) T-cells in addition to helper T-cells and B-cells. DCs existed in tissues and blood in their immature condition, handling foreign antigens for presentation to the immune system. DC maturation is triggered by antigen uptake, which leads to DC migration to lymph nodes, where they can interact directly with immune effector cells. Apart from antigen-specific CD8 cytotoxic T-lymphocytes (CTL), mature DCs were accomplished of inducing T helper type-1 immune responses; nevertheless, inside the tumor microenvironment, the DCs increase cancer tolerance, helping T helper type-2 responses. As a result, DCs can take advantage of both the significant positive and negative effects on cellular immune responses particular to malignant tumors. DC vaccines are typically made up of autologous monocytes that have been developed ex-vivo and then pulsed with antigen shortly formerly being injected (Figure 1). Thousands of people of various ages with a range of tumor types have received these vaccinations, and they have been well tolerated with only little adverse effects other than superficial skin irritation[5].

* Assistant Professor
College of Applied Medical Sciences
Clinical Laboratory Sciences Department, University of Hafr Albatin
Saudi Arabia. E-mail: hajirsh@uhb.edu.sa



Figure 1: Main characteristics of immature and mature dendritic cells

Despite the fact that active immune reactions have been documented in a many of clinical trials, the period plus the intensity of immune reactions have been inconsistent, and unbiased clinical responses have been unsatisfactory. Sipuleucel-T, an autologous dendritic cell vaccination with a recombinant antigen consisting of prostatic acid phosphatase linked to GM-CSF as an adjuvant, was the only DCs vaccine to receive FDA approval after demonstrating sufficient effectiveness in a Phase III clinical trial[6].

Despite the fact that this vaccination was developed for adult tumors, its success suggests that a successful DCs vaccine may be developed for juvenile cancers. To present, clinical responses to DCs vaccinations in pediatrics with solid masses of cancer have been unsatisfactory, with good tolerability but low efficiency in both high-grade neurological malignancies and a more diversified group of recurring solid malignant tumors. DCs production, antigen loading, ex-vivo maturation, and injection with or without adjuvant were all opportunities to improve the efficiency of the vaccine (Figure 2)[7].



Figure 2: Vaccination with Dendritic Cells DCVs are created and administered via a multi-step process. DC must be made from a cell source, the target antigen must be identified, and dendritic cells must be exposed to the antigen for maturation, and DCV must be given via synchronized immune modulators or vaccine adjuvants.

SOURCES OF DENDRITIC CELLS

DCs were made from peripheral blood mononuclear cells (PBMC) attained by phlebotomy or leukapheresis in the majority of immunotherapy clinical studies. This frequently results in continual vaccine generation; however, DC formation from a PBMC collection may not be appropriate for cases who have newly received chemotherapy or those with neurological malignancies who may necessitate steroid treatment[8].

The production of DCs from novel cell sources in paediatric patients has been described in three investigations. Following a hematopoietic stem cell transplant (HSCT) to get an allogeneic DCs vaccination produced from PBMC harvested from his stem cell donor, one patient developed residual active leukemia (9). Krishnadas et al. (2015)[10] described a patient with neuroblastoma who received DCs from a cryopreserved, GM-CSF mobilized PBSC product, and Nair et al. (2015)[11] stated on the possibility of producing DCs in patients with medulloblastoma using cryopreserved autologous PBSC products (Figure 3).



Figure 3: Immunotherapy using dendritic cells in malignant cases. Dendritic cells are formed from progenitors and differentiated via a variety of stimuli before being loaded with antigen and/or maturing. Dendritic cells that have matured are re-administered to the patient.

Nair et al. (2015)[11] revealed 3/5 samples yielded phenotypic DCs, while 2/5 samples yielded functional DCs. While they met the requirements for the creation of DCs, the results were consistent with Jacobs et al. (2007)[12] findings indicating the production of functional DCs from children with current malignancies is likely to be lower than from healthy adult donors. This was most probable for a combination of factors, including the malignant cells' immunosuppression or tolerance impact, in addition to preceding myelo- and/or immunosuppressive medication.

PBSC might be a striking foundation of DCs as they could be collected preceding to the beginning of chemotherapy or even prompted from an allogeneic source, avoiding the necessity of culturing these cells from an immunocompromised patient. Nevertheless, PBSCs could too a challenging source of DCs for GCSF mobilization could possibly twist DCs to a DC-2/tolerogenic phenotype constructing them a deprived choice for an immunotherapy product[13].

DCs were created by Zeng et al. (2015)[14] from embryonic stem cells, pluripotent stem cell lines, and (iPSCs) induced pluripotent stem cells. In most cases, these DCs were able of inducing natural killer (NK) cell

responses or antigen specific cytotoxic T lymphocyte (CTL) responses ex-vivo, and in vivo efficacy was demonstrated by cancer decline and prolonged survival in mice tumor models.

De Haar et al. (2015)[15] developed a method for manufacturing DCs from a portion of a cord blood unit utilized for HSCT, allowing the affected persons to be vaccinated with allogeneic DCs from their HSCT cord blood donor.

ANTIGEN SELECTION AND LOADING

The antigen of cancer cells that was loaded onto DCs has to be chosen carefully in order to have the best immune response possible. If a tumor specific antigen is identified, it must be used; however, many malignant tumors have no reliable tumor related antigens (TAAs). Complete tumor lysate, HLA-restricted epitopes, and mixtures of peptides from whole antigen are all options for antigens. Each of these antigen sources has its own set of benefits and drawbacks, and many studies have been conducted to determine which antigen is best for stimulating the immune system in the case of a certain cancer.

Precise cancer antigen epitopes offer the advantages of being recognized, immunogenic, plus readily accessible from non-autologous sources. However, the usage of specific epitopes restricts immunotherapy to those with a specific HLA profile. This difficulty could be solved by combining numerous intersecting peptides from a single protein, assuming that an epitope library is constructed in a non-HLA restricted manner[16].

Some TAA peptide assemblies were commercially available, albeit differences in alignment between lots could affect vaccine immunogenicity. The usage of an HLA restricted Wilms' tumor 1 epitope in persistent high grade glioma patients and a non-HLA restricted pancreatic bile salt protein in pancreatic adenocarcinoma patients are examples of researched tumor specific antigens[17].

Okamoto et al. (2016)[18] reveled that, to expand the applicability of this technology, researchers pulsed autologous DCs with a fusion of HLA class II-restricted WT1 peptide (WT1-II) in addition to HLA class I-restricted peptide (WT1-I) found better event free survival (EFS) plus overall survival (OS) in cases who had positive Delayed-type hypersensitivity DTH skin testing to either antigen following the injection. Krishnadas et al. (2015)[19] available results of a Phase I trial of a DCs vaccine targeting the malignancy germline antigens MAGE-A3, (CGA) MAGE-A1, and NY-ESO-1 in pediatric with malignant solid malignant tumors who had formerly been shown to increase the expression of these antigens in response to the demethylation chemotherapy agent decitabine (DAC). DAC treated patients to upregulate CGA followed by autologous DC-vaccine injection pulsed with commercially found intersecting peptides derived from each of these three antigens, allowing the registration of patients regardless of their HLA background.

If an immunogenic TAA could not be recognized, DCs pulsed with whole cell mRNA or whole cell protein were used as a treatment alternative. In pediatric DC immunotherapy, autologous tumor protein lysates have been commonly employed. The fact that tumor antigen can be found in lysate, especially in malignancies with poorly characterized antigens, is a strong point of this method. However, this procedure is limited to people with assessable and respectable malignancies because malignant tissue must be obtained. As a result, this procedure necessitates the creation of tailored vaccines, that spend more time and may decrease the availability of this therapy. Attaining live cells from the autologous cancers could allow for the isolation of cancer stem cells (CSCs) residents for selective CSCs lysate pulsing in short-term culture. Because CSCs have been shown to be able of evading conventional chemotherapy, using DC-based immunotherapy to target antigens expressed by CSCs could result in better long-term cancer management[20].

However, there were worries about the potential production of autoreactive T lymphocytes directed against stem cells, particularly those derived from cancer. In a mouse breast cancer model, CSC antigen pulsed DCs were created and then re-inoculated with high efficiency, with no harm to the other stem cell populations[21].

Wang et al. (2015)[22] revealed the possibility of creating autologous cancer cell lysates from hepatocellular carcinoma patients was investigated. Short-term tumor cell culture was used to make the vaccine. Surprisingly, cancer cell culture success in their model was 100%, which they believe is due to the proper selection of growth media for propagating cells that meet stem cell parameters. With these hepatic "stem-like" cell lysates utilized to load DCs, there was no hepatotoxicity of the DCs vaccination in this potential study.

Autologous tumor whole-cell mRNA was another putative source of antigen. The expression of TAA in DCs is energized by electro-porated mRNA, leading to antigen presentation via MHC Class I molecules, and would lead to more sustained tumor antigen presentation than protein pulsing. This antigen source, which is identical to whole cell lysate, provides a broad range of tumor-relevant antigens.

In a Phase I clinical trial, glioblastoma patients used mRNA sequestered from autologous sphere-forming CSCs generated in short-term culture to establish tumor-specific T-cell propagation following immunization, in addition to enhanced free survival related to aged controls. Notably, no autoimmunity was observed, particularly in myeloid stem cells and ocular (neural) tissue[23].

In 2015, researchers presented a follow-up examination of 30 melanoma patients treated with autologous mRNA DCs immunization. These selected cases had micrometastases but no detectable illnesses when they were vaccinated. Despite 2-year and 4-year survival rates of 93 percent and 70%, respectively, which were at least 10% higher than old controls after 4 years, the median survival has not been reached after 6 years of therapy termination[24].

Excitingly, the EFS was not enhanced, but the deteriorations were all early and these cases were efficiently rescued, resulting in excellent OS. Lag time to vaccine response was needed for DCs compelled anti-tumor immunity to improve[25].

Because autologous malignant tumor tissues may not be available in all patients, allogeneic tumor cell lines were used as an alternate source of cancer antigens. Even though the cell lines for the same cancer category differed, the similarities to a patient tumor were likely to outnumber the differences, so it's likely that DCs loaded with lysates from a cell line could produce results similar to autologous tumour loading, obviating the need for surgical procedures. In a research of eight immunized individuals with persistent brain cancers, three of whom were children, this technique was found to be safe. In addition, cases with stable illness after vaccination had an increase in IL-17 production, CD8 memory T-cells, and natural killer cells, in addition to a reduction in myeloid derived suppressor cells (MDSC), indicating that immune reactions to many public antigens could be a probable clarification for tumor maintenance in these cases. Nonetheless, the significance was not reached; also, CTLA-4 levels were lower in cases of stable malignancy, suggesting that this could be a potential target for immune regulation[26].

Ingesting a range of unique methods that integrated an alternate supply of DCs with a large number of tumor antigens was described by Zeng et al. (2015)[27]. Because pluripotent stem cells could be passaged in culture, tumor antigen DNA could be directly transduced into DCs for stable expression on MHC class I and II molecules. This technique was used to demonstrate effective and long-lasting CTL activation using a new source of DCs and stable transduction of numerous popular tumor antigen DNA. With DCs generated from human stem cells, transduced with a common tumor antigen, cultured, and packed for fast application, this procedure was a first step in generating a conventional, non-autologous vaccine. If successful, this would steadily increase the number of people who could receive vaccines while also shortening the time it takes for vaccines to become available.

ADMINISTRATION OF DENDRITIC CELL VACCINES

The effectiveness of DC-based vaccinations could be influenced by a number of factors. The incidence of immunizations, method of administration, injection of adjuvant immune-enhancing mediators, and prime-boost vaccination techniques were among the factors that received special attention (Mosca et al., 2007)[28].

1. Route of Dendritic Cell Administration: In an effort to determine the optimal administration route, DCs have been delivered intradermally, intravenously (IV), subcutaneously, intra-nodally, intra-lymphatically, and lastly intra-tumorally. The production of effective antigen-specific immune reactions appeared to be impacted by adequate tracking of antigen-loaded DCs to the location(s) of antigen presentation, which was one goal that the route of delivery gained substantial attention. Researchers used indium-labeled monocyte-derived DCs delivered through subcutaneous, intravenous, or intradermal injection to evaluate DC trafficking following administration. DCs injected intravenously collected in the lungs and were then rearranged to the bone marrow and liver, but no tumors or lymph nodes were found. In certain cases, a minor fraction of intradermal injected DCs were limited to the localized lymphatics, while tracer accumulation was predominant in the lymph nodes after the subcutaneous injection[29].

Fong et al. (2001)[30] treated 21 metastatic prostate cancer patients with autologous DCs activated and produced in vitro with recombinant mouse prostatic acid phosphatase. Following activation, DCs were identified as having up-regulated maturation markers (e.g., CD83 and CD80) while preserving adhesion molecule expression (e.g., CD44 and LFA-1). The researchers discovered that CD62 ligand and CCR5 expression were both downregulated. They hypothesized that if DCs were given intravenously, the lack of CD62 ligand would reduce the capability of primary T cells by blocking lymphoid tissue entrance through the high endothelial venules. Active immune reactions were detected in all cases, although intralymphatic and intradermal delivery elicited IFN-gamma, whereas IV injection elicited a humoral response. Although DCs have the ability to prompt antigen-specific T cell reactions irrespective to administration method, the nature of the immune reaction may differ significantly dependent on which route was used, according to the researchers.

2. Immunization Schedule: Ribas et al. (2000)[31] found that numerous vaccinations with DCs transduced with the MART-1 gene led to a shift to a Th2 cytokine profile and limited defense against cancer challenge compared to a solitary immunization in a mouse model. Fas receptor knockout mice did not have the side effects of numerous vaccinations, implying a function used for Fas receptor-mediated clearance of antigen-specific interferon-gamma (IFN-gamma) creating T cells in reaction to various immunizations.

3. Use of Vaccine Adjuvants: DCs must move to a lymph node besides excite effector cells, moreover B-cells or CD8 T-cells, in order for vaccination to be effective. Also, DCs stimulate CD4 (helper) T-cells as well as prompt tolerance in the right circumstances. As a result, the creation of adjuvants to activate DC function and/or precise effector residents in vivo has become a significant area of research in DC immunotherapy. DCs rely on toll-like receptors (TLR) signaling for maturation, which leads to the production of MHC Class I and II molecules and the release of pro-inflammatory cytokines. TLR activation on DCs may potentially aid the start of Th1 immune responses[32].

Engel-Noerregaard et al. (2009)[33] stated significantly higher response rates in cases who take adjuvants as part of their vaccine regimen in malignant melanoma vaccination studies. Poly-ICLC (Hiltonol) was some double-stranded RNA rich in inosine and cytidine that activated TLR3 and stimulated DCs via a TLR-domain comprising adaptor initiating interferon (TRIF). In addition, enhanced interferon synthesis activated the NK and CD8 T cells. Whereas it has mainly been utilized in grouping with peptide vaccines, and not with autologous dendritic cells, it has been well-tolerated as a vaccine adjuvant in both adults and children because of its stimulatory impacts on DCs in addition to the effector cells.

Chang et al. (2015)[34] discovered that new adjuvants derived from identified recall antigens, natural sources, tumor derived immunogenic proteins, or proprietary costimulatory combinations were used. Intraperitoneal injections of Antrodia cinnamomea extracts boosted DCs activation in vivo, with amplified TH1 T cells in addition to augmented innate CD11 DCs in tumor draining lymph nodes, according to one investigation of naturally happening plant polysaccharides utilized in ancient Chinese medicine.

In another study, DCs activated ex-vivo with extracts from Colonopsis pilosulae and Astragalus membranaceous improved tumor control in a breast cancer mouse model[34]. Pre-treatment of cancer antigen pulsed DCs with -glutamic acid, uric acid, or pancreatic adenocarcinoma upregulated factor (PAUF), a protein naturally released by human pancreatic carcinomas, led to tumor reduction in murine tumor models, according to Wang et al. (2015). The tumor response to these adjuvants was abolished by co-therapy that inactivated or detached CTL, indicating that the mechanism of cancer killing was reliant on CTL activation by pulsed DCs. Adjuvant stimulation was eventually discovered to stimulate the TLR pathway in DCs in three of these cases.

The final significance of TLR in DC stimulation has been widely researched, and one of theme has developed: TLR stimulation in murine models cannot be reliably induced to human models since human and murine DCs express a distinct overlapping set of TLRs[35].

DCs can be developed in vitro or in vivo after being exposed to antigen. A study on clinical efficacy in melanoma of DCs electro-porated with TriMix, a named mixture of mRNA for CD70, CD40L, and a constitutively active TLR4, preceding to antigen loading, includes research on in vitro maturation and DC stimulation[36].

Co-injection of immune-stimulatory combinations with the DCs vaccine was one field of research for vaccine adjuvants. Mitchell et al. (2015)[37] distributed the outcomes of a randomized clinical study in which persons with lately diagnosed glioblastoma were given a DCs vaccine loaded with Cytomegalovirus phosphoprotein 65 (pp65) with or without tetanus toxoid pre-treatment (Td). According to the researchers, pretreatment cases increased the migration of DCs to vaccine draining lymph nodes as well as the production of interferon-

in post-vaccine ELISPOT testing. The researchers also displayed a significant rise in progression-free survival, with three instances still alive and disease-free after three years.

Mitchell et al. (2015)[38] used a mice model to compare wild type and CCL3 knock-out mice and found that enhanced DC migration was dependent on CCL3. The investigators also displayed that CCL3 is produced by CD4 T-cells that have been precisely activated by the tetanus-diphtheria toxoid (Td) memory response. Although this method has not been verified in pediatric, it could be used to treat pediatric cancers because the tetanus toxoid vaccine was introduced at the age of two months. Because cancer patients are immunosuppressed due to the tumor or their treatment, they require adjuvant therapy to optimize DC activity and effector cell stimulation.

4. Concomitant Immunomodulation: One of the consistent features of antigen-loaded DC immunotherapy in vitro is that the effectiveness of antigen-loaded DCs in triggering antigen-specific CTL responses did not always translate to an anti-tumor response in vivo. One probable clarification was that cancer provide an immunosuppressive micro-environment that causes T-cells with an immune-tolerance phenotype to become anergic. The immunomodulatory effect could play a key effect in altering the environment to permit cancer invasion via DC and CTL stimulation within the cancer. The PD-1/PD-ligand system was one of the method's most appealing targets. PD-1, when activated on the surface of T-cells initiate antigen specific anergy or even apoptosis. Numerous malignant kinds in addition to mature DCs have been revealed to express PD-ligand (PD-L1) on surface of the cell[39].

In ovarian carcinoma model, DCs initiate the expression of great levels of PD-L1, and blockade of PD-L1 improved stimulation of CTL via DC and cytokines shift from a principally IL-10 generating TH2 response to an IL-12 TH1 response[40].

Ge et al. (2013)[41] observed the effects of a-PD-L1 antibody treatment at different stages of the DCs vaccination process. They show that treating DCs with a-PD-L1 antibody improved their proliferation capacity and IL-12 expression, as well as stimulating T-cells in the existence of a-PD-L1 and increasing interferon secretion levels. They also confirmed that after mouse was co-injected with a-PD-L1, DCs vaccination against a PD-L1 expressing breast cancer model resulted in a significant enhancement in tumor size reduction.

While they found no evidence of autoimmunity in treated mouse, the systemic inhibition of the PD-1/PD-L1 system raised concerns about the possibility of blocking important self-tolerance mechanisms in the immune system. Van der Waart et al. (2015)[42] raised this concern, leading to new approaches to investigate PD-1/PD-L1 focused silencing.

In one study, healthy participants' DCs were infected with a lentiviral vector encoding short hairpin RNA (shRNA) for PD-L1, which resulted in the development of PD-L1 being retracted. Except for the loss of surface PD-L1 expression, Wang et al. (2014)[43] found no changes in the typical DC phenotype, but the cells treated with this method had improved capability to activate T-cell propagation, secretion of interferon- besides IL-12, and in vitro malignant cell eradication.

In an in vivo murine AML model, van der Waart et al. (2015)[44] investigated this additional use. Short interfering RNA (siRNA) against PD-L1 and/or PD-L2 was used to treat DCs generated from PBMC, which resulted in a 20-fold increase in in vitro propagation of antigen specific CD8 T-cells. Furthermore, co-infusion of these Ag-specific CTL with PD-L1 suppressed DC immunization resulted in a prolonged and enhanced antigen-specific CTL response. There was no systemic toxicity as a result of these adjustments to PD-1/PD-L1 expression on DCs.

Inhibition of IL-10 was another way to avoid the immunosuppressive effects of the tumor environment. MHC-I expression is reduced, NK cell function is suppressed, and critical DC costimulatory molecules are reduced by IL-10. In a model of murine breast cancer, an anti-IL-10 (blocking) antibody given 24 hours' prior DCs immunization improved NK cell responses and was related to a clinically and statistically significant reduction in cancer development and increased survival[45].

Dasatinib was a multi-tyrosine kinase inhibitor that showed promise in BCR-abl fusion-positive hematological cancers however had only minor special effects in other cancers. This drug inhibited the kinases cKIT and SRC, which are known to be important in the survival of MDSCs and Tregs, respectively. Low-dose oral dasatinib in combination with an anti-melanoma DC vaccine augmented cancer invasion of CTL and CD11 DC cells, reduced signaling via hypoxia-mediated pathways, and improved tumor expression of chemokines and pro-inflammatory cytokines, all of which led to a significant discount in cancer growth. Consequently, simultaneous modulation of immunosuppressive pathways might improve DCs-mediated anti-tumor immune reaction[46].

Malignant tumors have been revealed to cause immunosuppression via a diversity of mechanisms, involving changes in L-arginine metabolism and production of indoleamine 2,3 dioxygenase (IDO)[47]. Narita et al. (2013)[48] discovered that IL-6 activates the arginase pathway, which leads to DC-dependent CD4 T cell malfunction. This suggests that drugs that block IL-6, like situxilizumab (-IL-6) or tocilizumab (IL-6R), could improve DCV efficacy.

Furthermore, an in vitro model of monocyte-derived DC stimulation of anti-leukemic T-cell activity confirmed that PGE2 use in DC maturation improved IDO synthesis, which improved DC-driven T-cell proliferation considerably when co-cultured with an IDO inhibitor, Levo-1-methyl-tryptophan (L-1-MT). L-1-MT has been shown to reduce IDO in a mouse glioma model, however it has not been tested in people and is not available commercially[49].

5. Prime-Boost Strategy: One of the most prominent issues that could be attributed to the use of more sophisticated DCs preparations was immune reactions to non-TAA epitopes that could outnumber those to TAA epitopes. Subsequent successive immunizations with viral vector modified DCs, for example, cellular immune responses to foreign viral antigens may weaken opposing responses to encoded tumor antigens. Further troubling, neutralizing antiviral antibodies may render subsequent vaccines ineffective in boosting anti-TAA immune reactions. A policy that could support bypass this difficulty was to prime with one DC vaccine preparation and boost with a heterologous preparation (prime-boost approach)[50].

Tuttenberg et al. (2003)[51] discovered that DCs infected with an adenoviral construct producing the melanoma gp100 antigen in vitro elicited a strong antigen-specific T cell response against various gp100 epitopes, which was accompanied by high levels of IL-2 and IFN-gamma. Surprisingly, the researchers discovered that repeated re-stimulation resulted in a decrease in the gp100-specific response as well as an upsurge in the anti-adenoviral T-cell reaction. The researchers discovered that combining peptide pulsed DCs with adenoviral vector modified DCs in a prime-boost immunization strategy could lead to long-lasting antitumor T cell reactions.

DC-BASED CANCER VACCINES IN CLINICAL TRIALS

1. Malignant Melanoma: Immunotherapy clinical trials, including DCs-based vaccines, continue to be fruitful in the field of malignant melanoma. 16 metastatic melanoma patients were given IV vaccinations with monocyte-derived DC pulsed with dual HLA-A*0201-restricted melanoma peptides gp100(209-217:210M) and (tyrosinase(368-376:370D). Except for one case of comprehensive remission of pleural and lung diseases, 2 cases of established disease, and two cases of mixed reactions, the vaccine was generally well tolerated. Five cases had an immune response to tyrosinase or gp100 via IFN-gamma release, besides 4 of the 5 cases had malignancy regression or cancer maintenance, demonstrating concordance of clinical and immunologic reactions[52].

Banchereau et al. (2001)[53] used CD34+ progenitor-derived autologous DCs which subcutaneously injected and pulsed with 4 HLA-A-restricted melanoma peptides (MART-1, MAGE-3, tyrosinase, and gp100), in addition to influenza matrix peptide and KLH as control antigens, to immunize 18 patients with metastatic melanoma. Two people had progressive vitiligo as a result of the immunization, although it was usually well tolerated. 16 of the 18 patients established an immune reaction to the control antigens, with one or more of the melanoma peptides eliciting a stronger response. Excitingly, the researchers found a negative significant connotation among the clinical advancement and an immunologic reaction for two or fewer melanoma peptides.

Krause et al. (2002)[54] employed autologous monocyte-derived DCs to merge with gamma-irradiated primary autologous tumour cells via polyethylene glycol incubation. The researchers subcutaneously vaccinated 17 patients at monthly intervals with no major side effects. Only one instance had an incomplete response, another advanced but had some deposits recede, and a third case had illness stabilization for six months.

Smithers et al. (2003)[55] used DCs loaded with particulate hepatitis B surface antigen and acid-eluted autologous melanoma peptide to immunize nineteen individuals with metastatic melanoma (HBsAg). The toxicity was restricted to the onset of vitiligo, flu-like symptoms or the appearance of autoantibodies. Four of the nine instances with cellular responses to HBsAg (HBsAg responders) had objective clinical responses or illness stability, whereas none of the ten cases with no immunological response (HBsAg nonresponders) had any therapeutic benefit. Only one of the nine HBsAg responders had a melanoma peptide specific IFN-gamma response, while five of the nine HBsAg responders did. Consequently, it was appeared that the usage of regulator specific antigens to measure immune reaction might show a respected effect in the design of DCs vaccine trials.

2. Hematologic Cancers: Only a few hematological cancers, like B cell lymphoma and multiple myeloma which produce monoclonal immunoglobulins with idiotypes (Id) or distinct antigenic determinants. These idiotypes might be classed as TAA and treated with targeted immunotherapy because they are distinct and consistent in each patient. To treat four patients with follicular B-cell lymphoma, Hsu et al. (1996)[56] employed autologous DCs pulsed in vitro with tumor-specific idiotype protein. Three patients had clinical responses, while all four patients had tumor-specific cellular immune responses.

Titzer et al. (2000)[57] used CD34 stem cell-derived DCs pulsed with Id peptides to treat 11 instances of advanced myeloma. ELISpot immunologic investigation identified elevated anti-idiotype antibody serum titers in 3 out of 10 instances and augmented Id-specific T cell stimulation in 4 out of 10 cases. In one case, there was also a reduction in BM plasma cell infiltration.

Liso et al. (2000)[58] used peripheral blood progenitor cell transplantation (PBPCT), high-dose chemotherapy (HDC), as well as DC-based Id protein immunization to treat twenty-five myeloma patients. After HDC-PBPCT, patients received intravenous infusions of DCs containing Id protein or Id coupled to KLH, followed by subcutaneous boosts of Id-KLH conjugates. Only 4 out of twenty-six cases showed a KLH-specific cellular proliferative reaction, while twenty-four out of twenty-six cases showed an Id-specific proliferative response.

Reichardt et al. (1999)[59] used HDCcteri and PBSCT, followed by Id-pulsed DC and Id/KLH vaccinations, to treat twelve patients with multiple myeloma. Eleven of the twelve instances produced KLH-specific cellular proliferative reactions, 2 of the 12 cases had Id-specific responses, besides one of the twelve cases had a transient Id-specific CTL reaction, according to the researchers. The 9 individuals that achieved total remission included the 2 cases who produced an Id-specific cellular reaction, and these 2 cases remained in complete remission next to the immunization. The researchers established that DC-based Id vaccination was achievable after HDC-PBSCT and that these cases could mount Id- and KLH-specific T cell reactions.

3. Genitourinary Tract Malignancies: Small et al. (2000)[60] completed a phase I/II clinical trial in hormone-refractory prostate malignant patients who were given Provenge, an autologous dendritic cell preparation loaded in vitro with a recombinant prostatic acid phosphatase-GM-CSF fusion protein. Fever was the most prevalent side effect, but the immunizations were typically well tolerated. Immune reactions to the fusion protein were seen in every case, whereas immune responses to prostatic acid phosphatase were seen in only 38% of the cases. Six patients were found to have significantly lower PSA levels. The researchers discovered a link between the onset of sickness and the production of an immune response to PAP, as well as the dose of dendritic cells used.

In a phase I clinical investigation employing monocyte generated DCs transfected with full tumor RNA, Su et al. (2003)[61] observed 10 evaluable cases with metastatic renal cell carcinoma. Six of the seven evaluable themes confirmed the growth of tumor-specific T cells after immunization, and the researchers detected a modest toxicity profile. Surprisingly, rather than the normal renal self-antigens, the T cell reactions found in these individuals were directed towards renal TAA, like telomerase and onco-fetal antigen.

Cervical cancer appeared to be a good candidate for DC vaccination treatment due to the well-known etiologic role of human papillomavirus (HPV) infection. This notion is reinforced by the fact that immunising women against HPV type 16 (HPV16) using a viral particle-like vaccine stops cervical intraepithelial neoplasia from spreading. The efficacy of this technique may be linked to the capability of HPV16 viral-like elements to drive DC activation and maturation[62].

In PBMC from healthy people and TIL residents from cervical cancer patients, Santin et al. (2003)[63] observed that DCs pulsed with HPV16 and HPV18 E7 onco-protein increased tumor-specific cytotoxicity and generated antigen-specific CTL responses.

In 2 instances with uterine sarcoma and 6 cases with ovarian cancer, Hernando et al. (2002)[64] documented a phase I clinical study using DCs injected intradermally pulsed with KLH and autologous tumor lysates. Within the first 14 weeks, three instances experienced disease stability and five had tumor progression. Despite the fact that all instances but one showed immune reactions to KLH, reactions to cancer lysate were only noticed in one case by DTH reactivity, two cases by propagation test, and one case by interferon-gamma release. Despite this, the

researchers discovered that tumor lysate-loaded DCs provide protection and are available in situations of advanced gynecologic malignancies.

4. Gastrointestinal Malignancies: Kono et al. (2002)[65] achieved that DCs immunization in metastatic gastric cancer was the subject of a phase I clinical research. Nine HLA A2+ cases with HER-2/neu overexpressing gastric tumors were given an intradermal dose of HER-2(p369) peptide via DCs. The vaccines were well tolerated, with only a small clinical response in one patient and illness stabilization for the next three months in the other. Six of the nine instances had HER-2/neu-specific T cell responses, as measured by IFN-gamma production, and two cases had CTL activation. As a result, in advanced cases of gastric cancer, DC vaccination therapy was nontoxic and reasonable, and it could trigger HER-2/neu-specific Th1 cellular responses.

In ten cases of primary liver cancer, Iwashita et al. (2003) discovered the use of DCs immunotherapy (cholangio-carcinoma or hepatocellular carcinoma). Monocyte-derived DCs were grown in vitro and then pulsed with autologous tumor lysate, KLH, and TNF-alpha before maturing for additional 9 days. Non-adherent cells were harvested and injected into the inguinal lymph nodes. Although there was only one mixed clinical response and two additional responses identified as a drop in tumor markers after immunization, the cases suggest reasonable tolerability for this regimen. DTH reaction to KLH was seen in seven out of 10 patients. In this group of cases, our study demonstrated the protection and availability of immunotherapy, but it also revealed that additional vaccine customization to increase bioactivity may be required.

5. Other Malignancies: A phase I clinical trial of DC immunotherapy in seven patients of glioblastoma multiform and two cases of anaplastic astrocytoma was successfully completed by Yu et al. (2001)[66]**.** The patients received autologous peripheral blood dendritic cells pounded with peptides via intradermal vaccinations are eluted from the surface of autologous glioma cells. In two of four cases where surgery recurred after DC vaccination, the researchers discovered infiltration of cytotoxic and memory T-cells[66]**.**

Autologous DCs pulsed with HER-2/neu- or MUC1-derived peptides were utilized to vaccinate advanced breast and ovarian cancer patients, according to Brossart et al. (2000)[67]**.** Crrelease assays would detect peptide-specific CD8+ T cell reactions in the peripheral blood in 5 out of 10 cases, in addition to intracellular IFN-gamma labelling. They assume that the HER-2/neu-derived E75 and MUC1-derived M1.2 peptides reflect immune-dominant epitopes because the reactions were typically strong and long-lasting (over 6 months). Excitingly, 2 cases developed immune reactions against malignante antigens other than those enclosed within the vaccine, signifying that antigen distribution occur in some cases who stand significant T cell reaction as a derivative of cancer vaccines.

Stift et al. (2003)[68] used autologous tumor lysate loaded DCs to immunize twenty patients with various stages of cancer (medullary thyroid carcinoma, pancreatic cancer, cholangiocarcinoma, and hepatocellular carcinoma). They used magnetic bead isolation to separate CD14+ monocytes, then used IL-4 and GMCSF to produce DCs in vitro, pulsed them with autologous tumor lysate, and matured them with TNF-alpha. Following each immunization, the patients were given adjuvant systemic IL-2 and DCs were delivered intra-nodally under ultrasound guidance.

The immunization process, on the other hand, was well tolerated, with no partial or total response. Nonetheless, objective proof of a clinical response, manifested as a decrease in tumour markers or a mixed response of quantifiable tumor deposits, was found in a few of instances. In addition, 18 instances exhibited a positive DTH reaction, and 3 cases showed an antigen-specific cellular reaction triggered by IFN gamma production. As a result, this approach of intra-nodal DC immunization combined with systemic IL-2 therapy appeared to be rational and well tolerated, with various biological activities in cases with advanced malignancies.

SUMMARY

Antigen-presenting cells are known as dendritic cells (DCs) with abundant MHC and costimulatory molecules, which facilitate antigen presentation. DC-based cancer vaccines have received a lot of attention in recent years because cancer patients' immune systems may have limited or faulty antigen presentation. DC loaded in a variety of ways can generate tumor antigen specific immune reactions.

Vaccines for prophylaxis and therapy have distinct rationales. Therapeutic vaccines, rather than avoiding disease, operate as a replacement or addition to existing medicines, and are used to treat both chronic infectious illnesses and cancer with active immunotherapy. The most promising uses of therapeutic immunisation in the setting of viral chronic diseases are vaccines against hepatitis B virus (HBV) and human papillomavirus (HPV), which could serve as a dual antiviral and cancer prevention method.

The main research efforts in the field of cancer vaccines are concentrated on the development of vaccination regimens with the primary goal of breaking tolerance to self-tumor-associated antigens, whereas immune protection against viruses that cause human cancers is ignored (TAAs). On the other hand, preclinical study for prophylactic anticancer vaccination based on TAAs expressed in premalignant phases is still in its initial stages. Despite the fact that preventative vaccination strategies for high-risk persons or those with a family history of cancer may be a future intervention option, the present description of cancer vaccines denotes to therapeutic immunization in cancer cancer.

Several scientists and doctors have worked for years to find successful immunotherapy treatments for cancer patients. The discovery in the 1890s by William Coley that administering bacterial extracts (Coley's toxins) to cancer patients could activate general systemic immunity, with a portion of it directed against the tumor, was the first proof that manipulating the immune system could encourage an effective antitumor reaction.

There's no denying that some cytokines can help cancer patients with their treatment. However, a significant number of cancer patients have had no or a poor response to treatment. This is due in part to inherent characteristics of host-tumor interactions, such as antigen processing/presentation defects, immune recognition escape via reduced or lost immunogenic peptides in connotation with MHC antigens, reduction of costimulatory signals, in addition to secretion of immunosuppressive cytokines.

Furthermore, in clinical immunotherapy research, infusions of large doses of cytokines frequently result in significant damage. As a result, considerable efforts are now being made to discover novel, safe, and effective immunotherapeutic approaches.

In vitro manipulation of specific cell kinds produced directly from persons and their introduction to one or more cytokines prior to reinfusion, with a toxicity profile that appears to be minor or nonexistent in patients, is now possible because to breakthroughs in biotechnology and immunology. Different types of DCs can be utilized not only as

excellent cellular adjuvants for therapeutic vaccines against cancer and severe infections, but also in transplantation and autoimmune disorders under certain conditions, thanks to their cytokine-mediated flexibility.

Preclinical research has devised and characterised sophisticated methods for producing dendritic cell-based cancer vaccines. The safety and feasibility of these methods have been confirmed by a number of studies. Before fully effective dendritic cell vaccines are available for cancer treatment, a few hurdles must be surmounted. To manage critical immunoregulatory systems in a predictable manner, the first step is to have a molecular understanding of them. The second goal is to uncover, optimise, and choose the optimal molecular signal combination to produce strong and clinically significant antitumor immunotherapy. The third goal is to create standard cellular processing and immunological monitoring methods that will allow important multi-center cancer vaccination trials to be conducted. Finally, the most suitable subset(s) of cases to test each vaccine in large-scale trials must be identified as the best vaccine nominees.

Authorship Contribution: All authors share equal effort contribution towards (1) substantial contributions to conception and design, acquisition, analysis and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of the manuscript version to be published. Yes.

Potential Conflict of Interest: None.

Competing Interest: None.

Acceptance Date: 28 September 2021

REFERENCES

1. Vineis P, Wild CP. Global cancer patterns causes and prevention. Lancet 2014; 383(9916):549-57.
2. Anguille S, Smits EL, Lion E. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15(7):e257-67.
3. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342(6165):1432-3.
4. Van Lint S, Wilgenhof S, Heirman C. Optimized dendritic cell-based immunotherapy for melanoma: The TriMix-formula. Cancer Immunol Immunother 2014;63(9):959-67.
5. Mitchell DA, Sayour EJ, Reap E, et al. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunol Res 2015;3(4):320-5.
6. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22.
7. Lasky JL III, Panosyan EH, Plant A, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 2013;33(5): 2047-56.
8. Hunn MK, Bauer E, Wood CE, et al. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neurooncol 2015;121(2):319-29.
9. Saito S, Yanagisawa R, Yoshikawa K, et al. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia. Cytotherapy 2015;17(3):330-5.
10. Krishnadas DK, Shusterman S, Bai F, et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother 2015;64(10):1251-60.
11. Nair SK, Driscoll T, Boczkowski D, et al. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. J Neurooncol 2015;125(1):65-74.
12. Jacobs JF, Hoogerbrugge PM, De Rakt MW, et al. Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediat Blood Cancer 2007;49(7): 924-7.
13. Haruta M, Tomita Y, Yuno A, et al. TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther 2013;20(5):504-13.
14. Zeng J, Wu C, Wang S. Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells. Sci Rep 2015;5:15262.
15. De Haar C, Plantinga M, Blokland NJ, et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. Oncoimmunology 2015;4(11):e1023973.
16. Elster JD, Krishnadas DK, Lucas KG. Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Human Vaccines and Immunotherapeutics 2016;12(9):2232-9.
17. Sakai K, Shimodaira S, Maejima S, et al. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. J Neurosurg 2015;123(4): 989-97.
18. Okamoto M, Kobayashi M, Yonemitsu Y, et al. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointest Pharmacol Ther 2016;7(1):133-8.
19. Krishnadas DK, Shusterman S, Bai F, et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother 2015;64(10):1251-60.
20. Lasky JL III, Panosyan EH, Plant A, et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 2013;33(5):2047-56.
21. Nguyen ST, Nguyen HL, Pham VQ, et al. Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations. Onco Targets Ther 2015;8: 323-34.
22. Wang X, Bayer ME, Chen X, et al. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol 2015;111(7):862-7.
23. Vik-Mo EO, Nyakas M, Mikkelsen BV, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013;62(9):1499-509.
24. Wilgenhof S, Corthals J, Van Nuffel AM, et al. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 2015;64(3): 381-8.
25. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22.
26. Olin MR, Low W, McKenna DH, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(C)IL17(C) response. J Immunother Cancer 2014;2:4.

27. Zeng J, Wu C, Wang S. Antigenically Modified Human Pluripotent Stem Cells Generate Antigen-Presenting Dendritic Cells. Sci Rep 2015;5:15262.
28. Mosca PJ, Hobeika AC, Clay TM, et al. Dendritic cell vaccines. Frontiers in Bioscience 2007;12:4050-60.
29. Morse MA, Coleman RE, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999;59(1):56-58.
30. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001;166(6):4254-9.
31. Ribas A, Butterfield LH, Hu B, et al. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res 2000; 60(8):2218-24.
32. Baxevanis CN, Voutsas IF, Tsitsilonis OE. Toll-like receptor agonists: current status and future perspective on their utility as adjuvants in improving anticancer vaccination strategies. Immunotherapy 2013;5(5):497-511.
33. Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58(1):1-14.
34. Chang WT, Lai TH, Chyan YJ, et al. Specific medicinal plant polysaccharides effectively enhance the potency of a DC-based vaccine against mouse mammary tumor metastasis. PloS One 2015;10(3):e0122374.
35. Seth A, Heo MB, Sung MH, et al. Infection-mimicking poly (gamma-glutamic acid) as adjuvant material for effective anti-tumor immune response. Int J Biol Macromol 2015; 75:495-504.
36. Benteyn D, Van Nuffel AM, Wilgenhof S, et al. Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules. Methods Mol Biol 2014;1139:3-15.
37. Mitchell DA, Sayour EJ, Reap E, et al. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunol Res 2015;3(4): 320-5.
38. Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015;519(7543):366-9.
39. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Med 2002;8(8):793-800.
40. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med 2003;9(5):562-7.
41. Ge Y, Xi H, Ju S, et al. Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett 2013;336(2):253-9.
42. Van der Waart AB, Fredrix H, Van der Voort R, et al. SiRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(C) T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunol Immunother 2015;64(5):645-54.
43. Wang S, Wang Y, Liu J, et al. Silencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro. Onco Targets Ther 2014;7:1389-96.
44. Van der Waart AB, Fredrix H, Van der Voort R, et al. SiRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(C) T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunol Immunother 2015;64(5):645-54.
45. Rossowska J, Anger N, Kicielinska J, et al. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response. Immunobiology 2015;220(3):389-98.
46. Lowe DB, Bose A, Taylor JL, et al. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 2014;3:e27589.
47. Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest 2012;41(7):765-97.
48. Narita Y, Kitamura H, Wakita D, et al. The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(C) T cell dysfunction in tumor-bearing mice. J Immunol 2013;190(2):812-20.
49. Trabanelli S, Lecciso M, Salvestrini V, et al. PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res 2015;253191.
50. Moingeon P. Strategies for designing vaccines eliciting Th1 responses in humans. J Biotech 2002;98(3):189-98.
51. Tuettenberg A, Jonuleit H, Tuting T, et al. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Gene Ther 2003;10(3):243-50.
52. Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24(1):66-78.
53. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61(17):6451-8.
54. Krause SW, Neumann C, Soruri A, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002;25(5):421-8.
55. Smithers M, O'Connell K, MacFadyen S, et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother 2003;52(1):41-52.
56. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2(1):52-8.
57. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br J Hematol 2000;108(4):805-16.
58. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6(6):621-7.
59. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study. Blood 1999;93(7):2411-9.
60. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18(23):3894-903.
61. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res 2003;63(9):2127-33.
62. Munoz N, Bosch FX, De Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl J Med 2003;348(6): 518-27.

63. Santin AD, Bellone S, Palmieri M, et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 2003;89(2):271-80.
64. Hernando JJ, Park TW, Kubler K, et al. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: Clinical and Immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51:45-52.
65. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002;8(11):3394-300.
66. Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61(3):842-7.
67. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-8.
68. Stift A, Friedl J, Dubsky P, et al. Dendritic cell-based vaccination in solid cancer. J Clin Oncol 2003;21(1):135-42.